Brokers Offer Predictions for PTCT FY2026 Earnings

PTC Therapeutics, Inc. (NASDAQ:PTCT) – Research analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for PTC Therapeutics in a research note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst K. Kluska expects that the biopharmaceutical company will post earnings of ($2.69) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $112.00 target price on the stock. The consensus estimate for PTC Therapeutics’ current full-year earnings is ($4.52) per share.

PTC Therapeutics (NASDAQ:PTCT) last posted its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported $10.04 earnings per share for the quarter, topping analysts’ consensus estimates of $0.85 by $9.19. The business had revenue of $1.18 billion for the quarter, compared to analyst estimates of $437.16 million. The firm’s quarterly revenue was down 9.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($1.20) EPS.

PTCT has been the topic of a number of other research reports. Robert W. Baird reduced their target price on PTC Therapeutics from $70.00 to $66.00 and set an “outperform” rating on the stock in a report on Wednesday, May 7th. Morgan Stanley reissued an “overweight” rating and issued a $70.00 price target (up previously from $67.00) on shares of PTC Therapeutics in a research note on Friday, March 7th. Royal Bank of Canada boosted their price objective on shares of PTC Therapeutics from $57.00 to $58.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 7th. Wells Fargo & Company raised their price target on PTC Therapeutics from $68.00 to $74.00 and gave the company an “overweight” rating in a research note on Tuesday, May 27th. Finally, Bank of America upgraded shares of PTC Therapeutics from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $55.00 to $68.00 in a research note on Friday, May 9th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $63.75.

PTC Therapeutics Trading Down 0.8%

Shares of PTCT stock opened at $51.69 on Tuesday. The firm has a market capitalization of $4.10 billion, a price-to-earnings ratio of -8.70 and a beta of 0.51. The firm’s 50 day moving average is $46.40 and its 200-day moving average is $47.96. PTC Therapeutics has a 1 year low of $28.72 and a 1 year high of $58.38.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Strs Ohio purchased a new position in shares of PTC Therapeutics in the first quarter valued at about $438,000. Ellsworth Advisors LLC purchased a new stake in PTC Therapeutics during the first quarter valued at $588,000. Acadian Asset Management LLC lifted its stake in shares of PTC Therapeutics by 6.1% in the 1st quarter. Acadian Asset Management LLC now owns 37,435 shares of the biopharmaceutical company’s stock valued at $1,904,000 after purchasing an additional 2,140 shares during the last quarter. Intech Investment Management LLC boosted its stake in shares of PTC Therapeutics by 62.8% during the 1st quarter. Intech Investment Management LLC now owns 39,307 shares of the biopharmaceutical company’s stock worth $2,003,000 after purchasing an additional 15,167 shares during the period. Finally, Bayforest Capital Ltd purchased a new position in PTC Therapeutics during the 1st quarter valued at $415,000.

Insider Activity at PTC Therapeutics

In other news, EVP Lee Scott Golden sold 897 shares of the company’s stock in a transaction on Wednesday, April 2nd. The shares were sold at an average price of $46.95, for a total value of $42,114.15. Following the completion of the sale, the executive vice president now owns 75,997 shares of the company’s stock, valued at approximately $3,568,059.15. This represents a 1.17% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Mark Elliott Boulding sold 1,929 shares of the company’s stock in a transaction dated Thursday, May 15th. The shares were sold at an average price of $46.18, for a total transaction of $89,081.22. Following the transaction, the vice president now directly owns 103,901 shares of the company’s stock, valued at approximately $4,798,148.18. This trade represents a 1.82% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 27,034 shares of company stock worth $1,405,767. 5.50% of the stock is owned by corporate insiders.

About PTC Therapeutics

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.